Back to Authors

Park, Keunchil

0000-0002-4846-7449

A5030107272 | I1343551460

Mayo Clinic

The University of Texas MD Anderson Cancer Center

Citations 4

Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer

Future Oncology | July 16, 2024 | Volume: 20 | Issue: 32 | Pages: 2409-2421

10.1080/14796694.2024.2371698 | PMID 39012623

First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS2597-TPS2597

10.1200/jco.2016.34.15_suppl.tps2597

MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 2508-2508

10.1200/jco.2016.34.15_suppl.2508

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9070-9070

10.1200/jco.2016.34.15_suppl.9070